The Cooper Companies reported fiscal third quarter revenue of $1.066 billion, up 1% year-over-year, with GAAP diluted EPS of $2.24 driven by a $307.2 million discrete tax benefit from the favorable conclusion of a U.K. tax examination. Non-GAAP diluted EPS was $1.15, and free cash flow increased 66% to $273.0 million. The company also updated its full-year fiscal 2026 guidance, projecting total revenue between $4.229 billion and $4.252 billion with non-GAAP diluted EPS of $4.51 to $4.55. Concurrently, the Board completed a strategic review, deciding to retain CooperSurgical rather than sell it, and expanded the share repurchase authorization from $2 billion to $3 billion.

The Cooper Companies, Inc. has approved an expansion of its Board of Directors from nine to ten members, effective July 1, 2026. Paul Keel has been appointed to fill the new director position and will also join the company's Audit Committee on that date.

The Cooper Companies, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected nine directors and ratified KPMG LLP as the independent auditor with 177,458,340 votes in favor. Additionally, stockholders approved the company's executive compensation on an advisory basis with 162,890,748 votes in favor.

The Cooper Companies, Inc. issued a press release on March 5, 2026, reporting its financial results for the fiscal first quarter ended January 31, 2026. The filing serves as the formal announcement of these results, which are incorporated by reference via the attached press release.

The Cooper Companies, Inc. amended its 2021 Term Loan Agreement and 2024 Revolving Credit Agreement to extend the maturity of $950 million in term loans to February 3, 2031. Additionally, the company increased the cap on incremental term loans to the greater of $1.365 billion or 100% of consolidated EBITDA.